{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:50:18Z","timestamp":1782395418534,"version":"3.54.5"},"reference-count":24,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: The management of dyslipidaemia in Slovakia has undergone significant changes in recent years, particularly through the relaxation of prescription restrictions for existing medications and the introduction of new innovative molecules. Achieving target levels of LDL cholesterol (LDL-C) plays a key role in preventing the onset and progression of atherosclerosis-related cardiovascular (CV) diseases. The aim of this study was to analyse how these changes have affected the effectiveness of reaching target LDL-C levels in patients at very high CV risk. Methods: This project was conducted as a retrospective analysis of anonymised LDL-C values from 2020 to 2023 using data from a collaborating nationwide laboratory. Patients included were those diagnosed with acute coronary syndrome (ACS), stroke, and, more generally, those with high and very high CV risk. Target LDL-C values were assessed based on the 2019 ESC\/EAS guidelines. Results: A total of 363,020 LDL-C test records from 115,950 patients were evaluated over the four-year study period. Among patients diagnosed with ACS, 2.2\u20135% achieved target LDL-C levels in the respective years of observation 2020\u20132023. As many as 6.5\u20137.4% had LDL-C levels \u2265 4.9 mmol\/L. For patients with stroke, only 4\u20136.6% reached target LDL-C levels, while 5.6\u20136.7% had levels \u2265 4.9 mmol\/L. In the group with very high CV risk, only 1.7\u20133% achieved target levels, and 7.5\u20138.7% had extremely high LDL-C levels \u2265 4.9 mmol\/L. Despite these modest improvements, over 93.4% of patients in the highest-performing subgroup failed to reach the absolute guideline target threshold in 2023. Conclusions: While the lifting of prescription constraints and the introduction of innovative treatments correlates with a doubling of absolute target attainment and a contraction of extreme hypercholesterolemia, overall control remains critically low in Slovakia. Systematic, protocol-driven combination regimens and intensive follow-up are urgently needed.<\/jats:p>","DOI":"10.3390\/diagnostics16131980","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:37:55Z","timestamp":1782391075000},"page":"1980","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progress in Achieving LDL Cholesterol Target Levels in a High-Risk Patient Population in Slovakia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9789-3305","authenticated-orcid":false,"given":"Stefan","family":"Toth","sequence":"first","affiliation":[{"name":"Department of Histology and Embryology, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Kosice, Slovakia"},{"name":"Cardiology Outpatient Clinic, Kardiocomp, s.r.o., 040 01 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8554-9259","authenticated-orcid":false,"given":"Lukas","family":"Olsavsky","sequence":"additional","affiliation":[{"name":"Faculty Hospital Agel Kosice-Saca, 040 15 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8811-025X","authenticated-orcid":false,"given":"Pavol","family":"Fulop","sequence":"additional","affiliation":[{"name":"East Slovak Institute of Cardiovascular Diseases, 040 01 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Dvoroznakova","sequence":"additional","affiliation":[{"name":"East Slovak Institute of Cardiovascular Diseases, 040 01 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sevcik","sequence":"additional","affiliation":[{"name":"Faculty Hospital of Jan Adam Rayman, 080 01 Presov, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vanova","sequence":"additional","affiliation":[{"name":"Faculty Hospital Agel Kosice-Saca, 040 15 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viliam","family":"Weis","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Faculty of Medicine, Pavol Jozef Safarik University, 040 11 Kosice, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","article-title":"The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better","volume":"18","author":"Mhaimeed","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/eurheartj\/ehaa1080","article-title":"How low is safe? The frontier of very low (<30 mg\/dL) LDL cholesterol","volume":"42","author":"Karagiannis","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e029216","DOI":"10.1161\/JAHA.122.029216","article-title":"Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5\u2009Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial","volume":"12","author":"Goodman","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_4","first-page":"738","article-title":"Success in achieving LDL-C target values in a high-risk population in Slovakia: The SlovakLipid retrospective study","volume":"21","author":"Toth","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_7","first-page":"409","article-title":"Assessment of vitamin D levels in correlation with coronary computed tomography angiography results in a Slovak population","volume":"21","author":"Pella","year":"2024","journal-title":"Arch. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13019-021-01596-7","article-title":"Three-dimensional transesophageal echocardiography in diagnosis of intermediate atrioventricular septal defect in the adult: Case report and literature review","volume":"16","author":"Schusterova","year":"2021","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e20230221","DOI":"10.21470\/1678-9741-2023-0221","article-title":"The Association Between Ascending Aortic and Left Ventricular Dimensions in Patients After Aortic Valve Replacement","volume":"39","author":"Schusterova","year":"2024","journal-title":"Braz. J. Cardiovasc. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"Jankowski","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1093\/eurheartj\/ehae558","article-title":"Variation in secondary prevention of coronary heart disease: The INTERASPIRE study","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_13","first-page":"372","article-title":"Are we successful in achieving target values for LDL cholesterol in statin-treated patients? Results from the DYSIS I survey\u2013Slovak Republic","volume":"14","author":"Pella","year":"2015","journal-title":"Int. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II","volume":"266","author":"Gitt","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12471-025-01939-2","article-title":"PENELOPE 1-year follow-up: Legacy effect of a short protocol-led LDL-C-lowering strategy in patients after myocardial infarction","volume":"33","author":"Liem","year":"2025","journal-title":"Neth. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00508-024-02365-x","article-title":"25 years of lipid-lowering therapy: Secular trends in therapy of coronary patients","volume":"137","author":"Ratz","year":"2025","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.athplu.2025.03.002","article-title":"Real-world management of hypercholesterolemia in patients after acute coronary syndrome in Greece","volume":"60","author":"Massia","year":"2025","journal-title":"Atheroscler. Plus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3390\/jcm14072340","article-title":"Assessing LDL-C Levels and Lipid-Modifying Therapies in a Real-World Cohort of Patients with Atherosclerotic Cardiovascular Disease: The REALITY Study","volume":"14","author":"Campuzano","year":"2025","journal-title":"J. Clin. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4227941","DOI":"10.1155\/2024\/4227941","article-title":"Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study: LDL-Cholesterol Goals in Primary Care","volume":"2024","author":"Barrios","year":"2024","journal-title":"Cardiovasc. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Faggiano, A., Gualeni, A., Barbieri, L., Mureddu, G.F., Venturini, E., Giallauria, F., Ambrosetti, M., Ruzzolini, M., Maranta, F., and Silverii, M.V. (2025). Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020493"},{"key":"ref_21","first-page":"137","article-title":"T\u00fcrkiye\u2018de statin kullan\u0131m\u0131n\u0131n LDL-kolesterol d\u00fczeyleri \u00fczerine etkisinin de\u011ferlendirildi\u011fi sistematik derleme [Evaluation of statin use on LDL cholesterol levels in Turkey: A systematic review]","volume":"48","year":"2020","journal-title":"Turk Kardiyol. Dern. Ars."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40119-025-00397-6","article-title":"Cardiovascular Outcomes of Early LDL-C Goal Achievement in Patients with Very-High-Risk ASCVD","volume":"14","author":"Kim","year":"2025","journal-title":"Cardiol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.numecd.2023.09.023","article-title":"LDL-cholesterol target levels achievement in high-risk patients: An (un)expected gender bias","volume":"34","author":"Berteotti","year":"2024","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.athplu.2025.01.001","article-title":"Inclisiran: Early LDL-C target achievement in a real-life population","volume":"59","author":"Briani","year":"2025","journal-title":"Atheroscler. Plus"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/1980\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:14:29Z","timestamp":1782393269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/1980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":24,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16131980"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16131980","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}